From a clinical perspective, trials of CHK1 inhibitors (Phase I or II) are ongoing in solid tumors, breast cancer and ovarian cancer, suggesting that CHK1 inhibition could also be effective in pancreatic cancer with selection of appropriate patients [30]. Here, CHEK1 is linked to breast carcinoma.